Please ensure Javascript is enabled for purposes of website accessibility

Inovio to Start a Phase 1/2 Study of its COVID-19 Vaccine in South Korea

By Brian Orelli, PhD – Jun 4, 2020 at 7:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The study is scheduled to start this month.

Inovio (INO 2.68%) is partnering with the International Vaccine Institute and Seoul National University Hospital to run a phase 1/2 clinical trial of Inovio's COVID-19 vaccine INO-4800 in South Korea. The study, which is scheduled to begin later this month, will start with 40 participants and then expand into an additional 120 participants.

The study is being funded through a $6.9 million grant from the Coalition for Epidemic Preparedness Innovations. The Korea Center for Disease Control and Prevention/Korea National Institute of Health is also supporting the clinical trial.

In April, Inovio started a phase 1 clinical trial in the U.S. and expects to have data from the study by the end of this month. Assuming INO-4800 can generate neutralizing antibodies, Inovio plans to run a phase 2/3 study starting in July or August.

The duplication of the clinical trials in the U.S. and South Korea is likely due to the fact that people of Asian descent sometimes respond to treatments differently than other ethnicities. Many regulatory agencies in Asian countries require a separate study in Asians to gain approval for drugs.

Gloved hands giving an injection into a shoulder

Image source: Getty Images.

Inovio is trailing Moderna (MRNA 0.15%), which has already released some phase 1 data for its COVID-19 vaccine mRNA-1273. Moderna started a phase 2 study for the vaccine earlier this month and plans to launch a phase 3 study in July.

Fortunately for Inovio and the rest of the vaccine makers trailing Moderna, there should be plenty of potential patients available even if Moderna wins the race, since the company will likely be supply constrained as it ramps up production of mRNA-1273.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.73 (2.68%) $0.04
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$118.25 (0.15%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.